Suzhou SmartNuclide Biopharmaceutical Co., Ltd.
PrivateLast Round
Series C
Extension
Apr 9, 2024
Total Funding Raised
$43.44M
Company Overview
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series C Extension round in April 2024.
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. is a biotechnology company that develops innovative diagnostic and therapeutic radiopharmaceuticals for oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical Imaging, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Comparables
Compare Suzhou SmartNuclide Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 82% | |
| Boomray Pharmaceuticals Co., Ltd. | 80% | |
| Sanofi | 78% |
For institutional investors. Book with your work email.
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Apr 9, 2024 | ||||
| Series C | Jul 7, 2021 | ||||
| Series B | Apr 23, 2020 | ||||
| Series A Extension | Nov 1, 2018 | ||||
| Series A | Mar 22, 2018 | ||||
Angel | Mar 1, 2016 |
For institutional investors. Book with your work email.
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agricultural Bank of China International | Series C |
| Longmen Capital | Series A Extension |
| Oriza Holdings | Series C Extension |
| Peppermint Venture Partners | Angel |
| Jiuyo Capital Management | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors increased 206% MoM.
- Apr 9, 2024
$14M round led by Oriza Holdings
For institutional investors. Book with your work email.
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Suzhou SmartNuclide Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.
Is Suzhou SmartNuclide Biopharmaceutical Co., Ltd. a public or private company?
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. is a private company.
What is the current stock price of Suzhou SmartNuclide Biopharmaceutical Co., Ltd.?
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Suzhou SmartNuclide Biopharmaceutical Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Suzhou SmartNuclide Biopharmaceutical Co., Ltd. worth (valuation)?
Valuation information for Suzhou SmartNuclide Biopharmaceutical Co., Ltd. is not publicly available.
Can I buy Suzhou SmartNuclide Biopharmaceutical Co., Ltd. stock?
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Suzhou SmartNuclide Biopharmaceutical Co., Ltd.'s last funding round?
Suzhou SmartNuclide Biopharmaceutical Co., Ltd.'s most recent funding round was Series C Extension on April 9, 2024.
Who are the main investors in Suzhou SmartNuclide Biopharmaceutical Co., Ltd.?
Key investors in Suzhou SmartNuclide Biopharmaceutical Co., Ltd. include Oriza Holdings.
Will Suzhou SmartNuclide Biopharmaceutical Co., Ltd. IPO soon?
No public IPO plans have been announced for Suzhou SmartNuclide Biopharmaceutical Co., Ltd..
How can I track Suzhou SmartNuclide Biopharmaceutical Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Suzhou SmartNuclide Biopharmaceutical Co., Ltd.'s shares on secondary markets.